Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Safety Trial Finds Risk of Blood Clots in Lungs and Death with Higher Dose of Tofacitinib in RA Patients; FDA to Investigate

americanpharmaceuticalreviewFebruary 27, 2019

Tag: immune system , RA , tofacitinib , blood clots

PharmaSources Customer Service